8-KFiled Aug 5, 8:00 PM ET

Lyell Immunopharma Reports Q2 2026 Financial Results

$LYEL · Lyell Immunopharma, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Lyell Immunopharma Reports Q2 2026 Financial Results

What Happened

  • Lyell Immunopharma, Inc. announced its financial results for the quarter ended June 30, 2026 by issuing a press release on August 6, 2026. The company filed a Form 8-K (Item 2.02) to disclose these quarterly results and attached the press release as Exhibit 99.1.

Key Details

  • Filing date: August 6, 2026 (Form 8-K).
  • Period reported: Quarter ended June 30, 2026.
  • Exhibit attached: Press Release dated August 6, 2026 (Exhibit 99.1).
  • Form sections reported: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).

Why It Matters

  • The 8-K signals Lyell has publicly released its most recent quarterly earnings and related financial information; investors should read the attached press release for specific metrics such as revenue, expenses, net income/loss, cash position and any guidance. This is a routine but material update that can affect short‑term trading and long‑term investment views depending on the detailed results and commentary in the press release.